Immunitybio Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Immunitybio
IBRX Stock  USD 9.78  0.23  2.41%   
Immunitybio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immunitybio's valuation are provided below:
Gross Profit
112.5 M
Market Capitalization
9.6 B
Enterprise Value Revenue
120.3694
Revenue
113.3 M
Earnings Share
(0.41)
We have found one hundred twenty available fundamental trends for Immunitybio, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immunitybio regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 4.9 B in 2026. Enterprise Value is likely to rise to about 5 B in 2026

Immunitybio Total Revenue

118.95 Million

Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.7 M, Interest Expense of 118.2 M or Total Revenue of 119 M, as well as many indicators such as Price To Sales Ratio of 15.27, Dividend Yield of 0.0 or Days Sales Outstanding of 130. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
Build AI portfolio with Immunitybio Stock
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Immunitybio Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets318.6 M501.9 M240.6 M
Slightly volatile
Short and Long Term Debt Total922 M878.1 M277.8 M
Slightly volatile
Total Current Liabilities101.4 M61.8 M77.4 M
Slightly volatile
Property Plant And Equipment Net97.4 M147.5 M73.5 M
Slightly volatile
Current Deferred Revenue85.5 K90 K251.1 K
Slightly volatile
Accounts Payable7.3 M7 M5.8 M
Slightly volatile
Cash94.6 M88.3 M71.4 M
Slightly volatile
Non Current Assets Total130.7 M187 M98.7 M
Slightly volatile
Cash And Short Term Investments168 M242.8 M126.8 M
Slightly volatile
Net Receivables44.7 M42.6 M7 M
Slightly volatile
Common Stock Total Equity50.7 K48.3 K19.4 K
Slightly volatile
Common Stock Shares Outstanding471.9 M919.9 M411.6 M
Slightly volatile
Liabilities And Stockholders Equity318.6 M501.9 M240.6 M
Slightly volatile
Non Current Liabilities Total986.7 M939.7 M280.3 M
Slightly volatile
Other Current Assets30 M28.5 M10.8 M
Slightly volatile
Other Stockholder Equity3.4 B3.2 B1.2 B
Slightly volatile
Total Liabilities1.1 B1 B354.5 M
Slightly volatile
Property Plant And Equipment Gross326.1 M310.6 M113.1 M
Slightly volatile
Total Current Assets187.9 M314.9 M141.8 M
Slightly volatile
Short Term Debt8.8 M9.3 M46.2 M
Slightly volatile
Intangible Assets9.3 M13 M7.2 M
Slightly volatile
Common Stock106 K101 K31.3 K
Slightly volatile
Other Assets8 M7.6 M2.9 M
Slightly volatile
Short Term Investments162.2 M154.5 M95.4 M
Slightly volatile
Capital Surpluse1.3 B2.2 B1.1 B
Slightly volatile
Property Plant Equipment173.5 M165.2 M67.7 M
Slightly volatile
Other Liabilities26.6 M25.3 M11.8 M
Slightly volatile
Long Term Debt428 M531.2 M320.5 M
Slightly volatile
Capital Lease Obligations43.9 M48.6 M29.6 M
Slightly volatile
Capital Stock59.8 K97.8 K47.6 K
Slightly volatile
Non Current Liabilities Other190.3 M327.8 M87.1 M
Slightly volatile
Deferred Long Term Liabilities129.6 K145.8 K159.1 K
Slightly volatile
Short and Long Term Debt402.1 M496.7 M340.3 M
Slightly volatile
Good Will728 K819 K893.9 K
Slightly volatile

Immunitybio Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization10.7 M15.5 M8.1 M
Slightly volatile
Total Revenue119 M113.3 M14.9 M
Slightly volatile
Other Operating Expenses222.8 M369.3 M168.5 M
Slightly volatile
Research Development118.1 M207.9 M89.2 M
Slightly volatile
Total Operating Expenses220.2 M368.6 M166.5 M
Slightly volatile
Selling General Administrative98.8 M194.1 M76.3 M
Slightly volatile
Selling And Marketing Expenses34.3 M32.6 M15.1 M
Slightly volatile
Interest Income1.9 M2.2 M3.3 M
Slightly volatile
Reconciled Depreciation17.6 M20.2 M15.3 M
Slightly volatile
Non Recurring544.8 K612.9 K669 K
Slightly volatile

Immunitybio Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation34.2 M31 M34.1 M
Pretty Stable
Begin Period Cash Flow99 M143.9 M74.7 M
Slightly volatile
Depreciation12.1 M20.2 M9.7 M
Slightly volatile
End Period Cash Flow99.9 M89.4 M75.4 M
Slightly volatile
Dividends Paid673 K708.4 K21.5 M
Pretty Stable
Issuance Of Capital Stock112.5 M128.1 M66.1 M
Slightly volatile
Cash Flows Other Operating2 M3.3 M1.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio15.2716.07714.9 K
Slightly volatile
Days Sales Outstanding1301377.5 K
Very volatile
Stock Based Compensation To Revenue2.552.69489
Slightly volatile
Capex To Depreciation0.430.451.4279
Very volatile
EV To Sales21.923.048415.1 K
Slightly volatile
Inventory Turnover0.660.740.8125
Slightly volatile
Days Of Inventory On Hand353397433
Slightly volatile
Sales General And Administrative To Revenue802544589
Slightly volatile
Research And Ddevelopement To Revenue1.741.8349334
Pretty Stable
Capex To Revenue0.510.54102
Very volatile
Cash Per Share0.30.2640.3002
Slightly volatile
Income Quality0.510.850.5888
Slightly volatile
Intangibles To Total Assets0.02640.02780.1159
Slightly volatile
Current Ratio10.195.09897.7151
Pretty Stable
Receivables Turnover2.792.65831.3776
Pretty Stable
Capex Per Share0.00840.00890.0331
Slightly volatile
Revenue Per Share0.130.12320.0171
Slightly volatile
Interest Debt Per Share1.131.07690.5441
Slightly volatile
Debt To Assets1.841.74960.8542
Slightly volatile
Operating Cycle5495787.6 K
Very volatile
Ebt Per Ebit0.891.37331.0506
Slightly volatile
Quick Ratio4.835.08417.3901
Pretty Stable
Net Income Per E B T1.10.99941.0031
Slightly volatile
Cash Ratio1.361.43044.0225
Pretty Stable
Days Of Inventory Outstanding353397433
Slightly volatile
Days Of Sales Outstanding1301377.5 K
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.251.171.1274
Pretty Stable
Fixed Asset Turnover0.730.767811.1353
Slightly volatile
Debt Ratio1.841.74960.8542
Slightly volatile
Price Sales Ratio15.2716.07714.9 K
Slightly volatile
Asset Turnover0.240.22570.0979
Slightly volatile

Immunitybio Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.9 B2.7 B5.2 B
Slightly volatile
Enterprise Value5 B3.3 B5.3 B
Slightly volatile

Immunitybio Fundamental Market Drivers

Immunitybio Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue90 K85.5 K
Total Revenue113.3 M119 M
Cost Of Revenue753 K715.4 K
Stock Based Compensation To Revenue 2.69  2.55 
Sales General And Administrative To Revenue 543.71  802.07 
Research And Ddevelopement To Revenue 1.83  1.74 
Capex To Revenue 0.54  0.51 
Revenue Per Share 0.12  0.13 
Ebit Per Revenue(2.26)(2.37)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY